Provectus Biopharmaceuticals, Inc. (PVCT) SEC Filings — 2024

Filings

• Provectus Biopharmaceuticals Enters Material Definitive Agreement — 8-K · Dec 26, 2024
• Provectus Biopharmaceuticals Files 8-K — 8-K · Dec 11, 2024
• Provectus Biopharma Ownership Update — SC 13D/A · Dec 6, 2024
• Provectus Biopharma Files 8-K on Director/Officer Changes — 8-K · Dec 5, 2024
• Provectus Biopharmaceuticals Files 8-K — 8-K · Nov 14, 2024
• Provectus Biopharma Files Q3 2024 10-Q Report — 10-Q · Nov 12, 2024
• Provectus Biopharma Appoints New Director and CMO — 8-K · Aug 19, 2024
• Provectus Biopharmaceuticals, Inc. SC 13G Filing — SC 13G · Aug 14, 2024
• Provectus Biopharma Files Q2 2024 10-Q — 10-Q · Aug 13, 2024
• Provectus Biopharm Enters Material Agreement, Reports Equity Sales — 8-K · Jul 17, 2024
• Pershing Edward Files SC 13D for Provectus Biopharmaceuticals — SC 13D · Jul 3, 2024
• Provectus Biopharmaceuticals Files 8-K with Material Agreement — 8-K · Jun 25, 2024
• Provectus Biopharmaceuticals Files 8-K on Security Holder Vote — 8-K · Jun 21, 2024
• Provectus Biopharma Files Proxy Statement — DEFA14A · Jun 20, 2024
• Provectus Biopharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024
• Provectus Biopharmaceuticals Announces 2024 Annual Meeting of Stockholders — DEF 14A · May 6, 2024
• Provectus Biopharmaceuticals Files 10-K/A Amendment — 10-K/A · Apr 29, 2024
• Provectus Biopharmaceuticals Director Departs — 8-K · Apr 16, 2024
• Provectus Biopharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024
• Provectus Biopharmaceuticals Files 8-K — 8-K · Mar 27, 2024
• Provectus Biopharmaceuticals Appoints New Chief Medical Officer — 8-K · Mar 26, 2024
• PROVECTUS BIOPHARMACEUTICALS Files Routine 8-K Disclosure — 8-K · Feb 22, 2024
• PROVECTUS BIOPHARMACEUTICALS Files 8-K on Feb 15 — 8-K · Feb 15, 2024